BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 15641040)

  • 1. Absence of V599E BRAF mutations in desmoplastic melanomas.
    Davison JM; Rosenbaum E; Barrett TL; Goldenberg D; Hoque MO; Sidransky D; Westra WH
    Cancer; 2005 Feb; 103(4):788-92. PubMed ID: 15641040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites.
    Cohen Y; Rosenbaum E; Begum S; Goldenberg D; Esche C; Lavie O; Sidransky D; Westra WH
    Clin Cancer Res; 2004 May; 10(10):3444-7. PubMed ID: 15161700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.
    Lee JH; Choi JW; Kim YS
    Br J Dermatol; 2011 Apr; 164(4):776-84. PubMed ID: 21166657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benign nodal nevi frequently harbor the activating V600E BRAF mutation.
    Taube JM; Begum S; Shi C; Eshleman JR; Westra WH
    Am J Surg Pathol; 2009 Apr; 33(4):568-71. PubMed ID: 19033861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.
    Saldanha G; Potter L; Daforno P; Pringle JH
    Clin Cancer Res; 2006 Aug; 12(15):4499-505. PubMed ID: 16899595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The oncogenic B-raf V599E mutation occurs more frequently in melanomas at sun-protected body sites.
    Deichmann M; Krahl D; Thome M; Wüst K; Hassanzadeh J; Helmke B
    Int J Oncol; 2006 Jul; 29(1):139-45. PubMed ID: 16773193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF mutations in conjunctival melanoma.
    Gear H; Williams H; Kemp EG; Roberts F
    Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2484-8. PubMed ID: 15277467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of BRAF mutations in uveal melanoma.
    Rimoldi D; Salvi S; Liénard D; Lejeune FJ; Speiser D; Zografos L; Cerottini JC
    Cancer Res; 2003 Sep; 63(18):5712-5. PubMed ID: 14522889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
    Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
    Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
    Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
    Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis.
    Wu J; Rosenbaum E; Begum S; Westra WH
    Am J Dermatopathol; 2007 Dec; 29(6):534-7. PubMed ID: 18032947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of mutations of the BRAF gene in malignant melanoma of soft parts (clear cell sarcoma of tendons and aponeuroses).
    Panagopoulos I; Mertens F; Isaksson M; Mandahl N
    Cancer Genet Cytogenet; 2005 Jan; 156(1):74-6. PubMed ID: 15588860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis.
    Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M
    Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    Yaman B; Akalin T; Kandiloğlu G
    Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF mutations in melanocytic tumors (nevi and melanomas) from organ transplant recipients.
    Kanitakis J; Baldassini S; Lora V; Euvrard S
    Eur J Dermatol; 2010; 20(2):167-71. PubMed ID: 19919912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF kinase in melanoma development and progression.
    DeLuca AM; Srinivas A; Alani RM
    Expert Rev Mol Med; 2008 Feb; 10():e6. PubMed ID: 18279546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MC1R germline variants confer risk for BRAF-mutant melanoma.
    Landi MT; Bauer J; Pfeiffer RM; Elder DE; Hulley B; Minghetti P; Calista D; Kanetsky PA; Pinkel D; Bastian BC
    Science; 2006 Jul; 313(5786):521-2. PubMed ID: 16809487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The T1799A BRAF mutation is present in iris melanoma.
    Henriquez F; Janssen C; Kemp EG; Roberts F
    Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):4897-900. PubMed ID: 17962436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma.
    Dong J; Phelps RG; Qiao R; Yao S; Benard O; Ronai Z; Aaronson SA
    Cancer Res; 2003 Jul; 63(14):3883-5. PubMed ID: 12873977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region.
    Amanuel B; Grieu F; Kular J; Millward M; Iacopetta B
    Pathology; 2012 Jun; 44(4):357-9. PubMed ID: 22614711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.